Vancouver, British Columbia — Kardium Inc., a medical technology company focused on cardiac care, has announced the close of a $250 million (CA$340 million) financing round to support the commercial launch of its Globe® Pulsed Field System for the treatment of atrial fibrillation (AF). The funding will also be used to expand manufacturing operations and build out the company’s commercial infrastructure.
The oversubscribed round was led by several new investors including Janus Henderson Investors, Qatar Investment Authority (QIA), MMCAP, Piper Heartland Healthcare Capital, Eventide Asset Management, and Eckuity Capital. Existing investors such as T. Rowe Price Associates, T. Rowe Price Investment Management, and Durable Capital Partners LP also participated. The financing includes an equity investment from a major strategic investor.
“We’re thrilled to have secured this transformational financing with a world-class syndicate of investors,” said Kevin Chaplin, CEO of Kardium. “This funding enables us to move ahead with the commercial launch of the Globe System by expanding our manufacturing capabilities and building a strong commercial team. Everyone at Kardium is energized by the opportunity to bring the Globe System to market and help improve the lives of millions of patients worldwide suffering from atrial fibrillation.”
Aaron Schaechterle, Portfolio Manager at Janus Henderson Investors, praised Kardium’s potential to transform AF care, calling the Globe System a “disruptive innovation with exemplary clinical outcomes.” He noted the system’s promise comes at a critical time as the field shifts toward pulsed field ablation technologies.
The funding follows strong results from the pivotal PULSAR clinical study, which were presented at the 2025 Heart Rhythm Society annual meeting. The data showed that 78 percent of paroxysmal AF patients treated with the Globe System remained free of atrial arrhythmia at one year, with zero device-related primary safety events reported.
The Globe Pulsed Field System includes a 122-electrode mapping and ablation catheter and advanced software that allows physicians to perform pulmonary vein isolation, high-definition mapping, and ablation throughout the atrium using a single catheter. The system is designed to simplify and improve AF procedures, delivering efficiency and precision in a single platform.
With this new capital, Kardium plans to pursue regulatory approvals, scale manufacturing, establish a commercial and clinical support team, and continue clinical research for broader applications of the Globe System ahead of its anticipated launch later this year.
